Compare ACRS & EVER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | EVER |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 928.5M |
| IPO Year | 2015 | 2018 |
| Metric | ACRS | EVER |
|---|---|---|
| Price | $5.87 | $24.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.20 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 1.8M | 738.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 198.86 |
| EPS | N/A | ★ 1.04 |
| Revenue | $1,683,000.00 | ★ $163,349,000.00 |
| Revenue This Year | N/A | $14.73 |
| Revenue Next Year | $4.24 | $11.51 |
| P/E Ratio | ★ N/A | $23.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.70 | $13.88 |
| 52 Week High | $6.52 | $28.73 |
| Indicator | ACRS | EVER |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 51.26 |
| Support Level | $4.13 | $24.31 |
| Resistance Level | $6.52 | $27.56 |
| Average True Range (ATR) | 0.37 | 1.37 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 57.14 | 52.64 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
EverQuote Inc operates an online marketplace for insurance shopping, connecting consumers with insurance providers, including carriers and agents. Its marketplace is powered by proprietary data and technology platform that delivers high-intent, pre-validated consumer referrals aligned with insurers underwriting and profitability requirements. The platform provides transparency and campaign management tools, enabling providers to evaluate marketing spend performance and manage return on investment. Consumers can visit insurance provider websites, engage by phone, or submit data to receive quotes. Services are free for consumers, and the company derives revenue principally from consumer inquiries sold as referrals to insurance providers. It derives a majority of revenue from Direct channels.